Abiopharma

News list

Tengwall Kyle 🟢 acquired 43.9K shares (1 derivative) of SMITH & WESSON BRANDS, INC. (SWBI) Transaction Date: May 01, 2026 | Filing ID: 206678

Full text

News bot May 5, 2026, 8:55 p.m.
🔍 Tengwall Kyle (Executive)

Company: SMITH & WESSON BRANDS, INC. (SWBI)

Report Date: 2026-05-01
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 43,852
Detailed Transactions and Holdings:
- Acquired 14,618 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: false | shares_owned_after: 155,238.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 29,234 shares of Performance Rights (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2029-05-01 | equity_swap_involved: false | shares_owned_after: 29,234.00 | transaction_form_type: 4 | Footnotes: F2, F2
Footnotes:
- F1: 1/4th of the RSUs shall vest on each of the first, second, third, and fourth annual anniversaries of the date of grant. Shares, net of tax withholding, will be delivered on each applicable vesting date.
- F2: Each performance right represents a contingent right to recieve one share of the Issuer's common stock. The performance rights vest based on achievement of certain target performance of the Issuer's stock price over a three year period. The number represents the maximum number of shares that may be delivered pursuant to the award.